Joseph Muenzer MD
Pediatric Endocrinology
Professor, Pediatrics, University of North Carolina at Chapel Hill School of Medicine
Join to View Full Profile
101 Manning DrChapel Hill, NC 27514
Phone+1 919-966-4131
Dr. Muenzer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical Center/Eunice Kennedy Shriver NICHDFellowship, Pediatric Endocrinology, 1982 - 1985
University of Wisconsin Hospitals and ClinicsResidency, Pediatrics, 1979 - 1982
Case Western Reserve University School of MedicineClass of 1979
Certifications & Licensure
NC State Medical License 1993 - 2026
MI State Medical License 1986 - 2002
WI State Medical License 1980 - 1999
MD State Medical License 1983 - 1985
American Board of Medical Genetics and Genomics Clinical Biochemical/Molecular Genetics
American Board of Pediatrics Pediatrics
Clinical Trials
- Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase Start of enrollment: 2004 Sep 13
- A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® Start of enrollment: 2009 Nov 18
- Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase® Start of enrollment: 2009 Jul 02
Publications & Presentations
PubMed
- Safety profile of idursulfase administered at home in patients with mucopolysaccharidosis II enrolled in the Hunter Outcome Survey.Barbara K Burton, Nathalie Guffon, Jane Roberts, Ans T van der Ploeg, Simon A Jones
Molecular Genetics and Metabolism. 2026-01-12 - An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II.Joseph Muenzer, Barbara K Burton, Paul Harmatz, Deepa S Rajan, Simon A Jones
The New England Journal of Medicine. 2026-01-01 - Female Patients With Mucopolysaccharidosis II (MPS II): Insights From the Hunter Outcome Survey.Barbara K Burton, Hernan Amartino, Roberto Giugliani, Christoph Kampmann, Julian Raiman
JIMD Reports. 2026-01-01
Press Mentions
FDA Pushes Back PDUFA Date for Regenxbio's Hunter Syndrome Gene TherapyAugust 19th, 2025- Family of NC 5-Year-Old with Rare Disease Searching for Hope After Drug Trial EndsMay 11th, 2021
- Applied Therapeutics to Host Virtual Rare Disease ForumMarch 16th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
